Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of normalising slightly elevated plasma glucose by Exenatide in acute ischemic stroke patients treated with intravenous thrombolysis: a pilot study

Trial Profile

Safety of normalising slightly elevated plasma glucose by Exenatide in acute ischemic stroke patients treated with intravenous thrombolysis: a pilot study

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exenatide (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 11 Sep 2016 Status changed from recruiting to discontinued.
  • 23 Jul 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top